1. Executive Summary
2. Research Methodology
3. Multiple Sclerosis
3.1 Overview
3.1.1 Symptoms of MS
3.2 Types of MS
3.3 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Type
4.2.2 Market Share by Mode of Administration
4.2.3 Market Share by Drug Class
4.2.4 Market Share by Region
5. Drug Analysis
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Products
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Drug Modifying Therapies for MS
7.1.2 Launch of New Drugs
7.1.3 Drugs Price Hike
7.2 Growth Drivers
7.2.1 Increasing Prevalence of Multiple Sclerosis
7.2.2 Ageing Population
7.2.3 Robust Drug Pipeline
7.2.4 Rising Healthcare Expenditure
7.2.5 Growth in per Capita Income
7.3 Challenges
7.3.1 Patent Expiration of Major Drugs
7.3.2 Stringent Regulatory Norms
7.3.3 Expensive Drugs
7.3.4 Side-effects of Drugs
8. Competitive Landscape
8.1 Product Landscape
8.2 Financial Analysis
8.3 Market Share Analysis
9. Company Profiles
9.1 Biogen Inc.
9.2 Teva Pharmaceuticals
9.3 Bayer AG
9.4 Sanofi Genzyme
9.5 Novartis AG
9.6 Pfizer Inc.